Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19,Journal of Antimicrobial Chemotherapy

当前位置： X-MOL 学术 › J. Antimicrob. Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19
Journal of Antimicrobial Chemotherapy ( IF 3.9 ) Pub Date : 2021-09-02 , DOI: 10.1093/jac/dkab321
Carolina Garcia-Vidal ₁ , Rodrigo Alonso ₁ , Ana M Camon ₁ , Celia Cardozo ₁ , Laia Albiach ₁ , Daiana Agüero ₁ , M Angeles Marcos _{2,

3} , Juan Ambrosioni ₁ , Marta Bodro ₁ , Mariana Chumbita ₁ , Lorena de la Mora ₁ , Nicole Garcia-Pouton ₁ , Gerard Dueñas ₁ , Marta Hernandez-Meneses ₁ , Alexy Inciarte ₁ , Genoveva Cuesta _{2,

3} , Fernanda Meira ₁ , Laura Morata ₁ , Pedro Puerta-Alcalde ₁ , Sabina Herrera ₁ , Montse Tuset ₄ , Pedro Castro ₅ , Sergio Prieto-Gonzalez ₆ , Alex Almuedo-Riera _{3,

7} , Josep Mensa ₁ , José Antonio Martínez ₁ , Gemma Sanjuan _{1,

8} , J M Nicolas ₅ , A del Rio ₁ , José Muñoz _{3,

7} , Jordi Vila _{2,

3} , Felipe Garcia ₁ , Alex Soriano ₁

Affiliation

The use of remdesivir has demonstrated a significant reduction in the time to recovery in patients with COVID-19. However, the impact on mortality is still controversial. Therefore, it is necessary to evaluate whether there is a specific subgroup of patients in whom an active antiviral therapy also reduces the mortality.

中文翻译：